Chitosan has ideal properties for the development of a new class of adjuvants and as a vaccine carrier. Even though extensive efforts to develop new adjuvants for human vaccines are made, the most widely used adjuvant is still aluminum hydroxide.
Despite the many attractive properties of chitosan as an adjuvant there are still limitations. The most prominent are low solubility, impurities, and batch-to-batch inconsistency.
The Viscosan® and ViscoGel® breakthrough technologies solve key obstacles to in vivo applications by providing a unique solution to the solubility problem and enabling controlled design and GMP manufacturing of pharmaceutical grade chitosan and viscoelastic gels with optimized properties.
ViscoGel® can be mechanically processed to a crushed gel of smaller particles. The particles offer a large surface area available for interaction with the immune system, enable injection through a fine needle, fast cell infiltration and efficient presentation of the antigen.
Viscogel AB - Gunnar Asplunds Allé 32, Hus D, 171 63 Solna, Sweden - firstname.lastname@example.org
Research and Development - Viscosan & ViscoGel, medical chitosans for a new class of adjuvants and vaccine carriers.